Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases.
Mach-Tomalska M, Pituch-Noworolska A, Bień E, Malanowska M, Machura E, Pukas-Bochenek A, Chrobak E, Pac M, Pietrucha B, Drygała S, Kamieniak M, Kasprzak J, Heropolitańska-Pliszka E. Mach-Tomalska M, et al. Among authors: drygala s. Immunotherapy. 2024 Apr;16(6):391-403. doi: 10.2217/imt-2023-0305. Epub 2024 Feb 16. Immunotherapy. 2024. PMID: 38362629 Free article.
Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies - real-world data from the IG TATRY study.
Heropolitańska-Pliszka E, Pac M, Pietrucha B, Machura E, Pukas-Bochenek A, Chrobak E, Bień E, Malanowska M, Pituch-Noworolska A, Drygała S, Kamieniak M, Kasprzak J, Mach-Tomalska M. Heropolitańska-Pliszka E, et al. Among authors: drygala s. Expert Rev Clin Immunol. 2023 Jul-Dec;19(10):1281-1291. doi: 10.1080/1744666X.2023.2240514. Epub 2023 Jul 25. Expert Rev Clin Immunol. 2023. PMID: 37489744
Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study.
Zagórowicz E, Cichoż-Lach H, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Filip R, Janiak M, Skrobot K, Kłopocka M, Liebert A, Kaczka A, Wojciechowski K, Drygała S, Michalak A. Zagórowicz E, et al. Among authors: drygala s. Adv Clin Exp Med. 2024 Jan;33(1):69-77. doi: 10.17219/acem/162969. Adv Clin Exp Med. 2024. PMID: 37166016 Free article.
Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study.
Eder P, Kłopocka M, Cichoż-Lach H, Talar-Wojnarowska R, Kopertowska-Majchrzak M, Michalak A, Filip R, Waszak K, Stawczyk-Eder K, Janiak M, Skrobot K, Liebert A, Zatorski H, Solarska-Półchłopek A, Krogulecki M, Pękała A, Poniewierka E, Smoła I, Kaczka A, Wojciechowski K, Drygała S, Zagórowicz E. Eder P, et al. Among authors: drygala s. Therap Adv Gastroenterol. 2023 Feb 14;16:17562848231151295. doi: 10.1177/17562848231151295. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 36818601 Free PMC article.
Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study).
Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Cichoż-Lach H, et al. Among authors: drygala s. Therap Adv Gastroenterol. 2021 Aug 30;14:17562848211036456. doi: 10.1177/17562848211036456. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34484422 Free PMC article.